Travere Therapeutic News

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to

GlobeNewswireJun 11 17:00 ET

Barclays Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $12

Barclays analyst Carter Gould maintains $Travere Therapeutic(TVTX.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 53.5% and

moomoo NewsJun 11 05:32 ET · Ratings

Travere Gains on Novartis Data for Filspari Rival, Calliditas Buyout

Seeking AlphaMay 28 13:35 ET

Press Release: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May

Dow JonesMay 15 17:00 ET

Travere Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities Health Care

GlobeNewswireMay 8 16:30 ET

Express News | Travere Therapeutics Inc : BofA Global Research Cuts Price Objective to $19 From $21

ReutersMay 8 06:57 ET

Travere Therapeutics Price Target Maintained With a $19.00/Share by HC Wainwright & Co.

Travere Therapeutics Price Target Maintained With a $19.00/Share by HC Wainwright & Co.

Dow JonesMay 7 14:20 ET

Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts

In the last three months, 6 analysts have published ratings on Travere Therapeutics (NASDAQ:TVTX), offering a diverse range of perspectives from bullish to bearish.The table below summarizes their rec

BenzingaMay 7 14:00 ET

Express News | Travere Therapeutics Shares Are Trading Higher Following Q1 Earnings

BenzingaMay 7 11:20 ET

Travere Therapeutics Is Maintained at Buy by Canaccord Genuity

Travere Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow JonesMay 7 10:30 ET

Express News | Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $18

BenzingaMay 7 10:20 ET

Travere Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 150.7% Canaccord Genuity $15 → $18 Maintains Buy 04/24/2024 164.62% HC Wainwright & Co. $17 → $

BenzingaMay 7 10:19 ET

Earnings Call Summary | Travere Therapeutic(TVTX.US) Q1 2024 Earnings Conference

The following is a summary of the Travere Therapeutics, Inc. (TVTX) Q1 2024 Earnings Call Transcript:Financial Performance:Travere recorded Q1 2024 total revenue of $41.4 million, up from $30.9 millio

moomoo AIMay 7 05:06 ET · Conference Call

Express News | Travere Therapeutics Inc : Canaccord Genuity Raises Target Price to $18 From $15

ReutersMay 7 03:48 ET

Travere Therapeutics Inc (TVTX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ...

Yahoo FinanceMay 7 03:07 ET

Travere Therapeutic | 10-Q: Quarterly report

SEC announcementMay 6 16:51 ET · Announcements

Travere Therapeutics Q1 2024 Adj EPS $(1.51) Misses $(0.99) Estimate, Sales $41.374M Miss $42.847M Estimate

Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(1.51) per share which missed the analyst consensus estimate of $(0.99) by 52.53 percent. This is a 64.13 percent decrease over losses

BenzingaMay 6 16:13 ET

Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q1 Revenue $41.4M, Vs. Street Est of $43.6M

04:07 PM EDT, 05/06/2024 (MT Newswires) -- Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q1 Revenue $41.4M, vs. Street Est of $43.6M

MT NewswiresMay 6 16:07 ET

Travere Therapeutics 1Q Rev $41.4M >TVTX

Travere Therapeutics 1Q Rev $41.4M >TVTX

Dow JonesMay 6 16:05 ET

Express News | Travere Therapeutics Inc - Company Continues to Anticipate That Operating Cash Use Will Decline Throughout 2024

ReutersMay 6 16:02 ET